[ Meet the Professor ] 10th Meet The Professor Advanced International Breast Cancer Course (AIBCC) Padua, November 6-8, 2014 The Conference will include: 1) Lectures: Internationally recognized speakers provide a balanced overview of selected topics 2) Clinical Case Discussions: Difficult or controversial cases related to the diagnostic or therapeutic management of early and advanced breast cancer will be presented. All participants will be requested to select their vote among a predefined list of options. Expert panelists will then provide their opinion and discuss the audience s choices. 3) Highlights: Internationally recognized speakers give an update of significant advances presented at major meetings (ASCO, ESMO, SABCS) on preselected topics 1 di 11
[Program] Thursday, November 6 th 8.00 Registration 8.45 Introduction to the Conference Pier Franco Conte, Gabriel N. Hortobagyi SESSION I-PATHOLOGY Chairmen: Alberto Amadori, Massimo Rugge 9.00 Standardization of breast cancer diagnosis: pathology Anna Sapino 9.30 Standardization of breast cancer diagnosis: genomics Giampaolo Bianchini SESSION II-LOCOREGIONAL THERAPIES Chairmen: Nicola Balestrieri, Graziano Meneghini 10.00 Evolving loco-regional management Post-mastectomy radiotherapy: a new standard? Philip Poortmans Do margins still matter? - Alberto Costa Hypofractionated breast irradiation- Philip Poortmans 11.00 Discussion 11.20 Coffee break SESSION III-IMAGING Chairmen: Gabriel N. Hortobagyi, Luigi Pescarini 11.40 Role of MRI in breast cancer diagnosis Clinical cases will be presented to discuss the following items: - Is MRI the standard screening procedure in young women? Enrica Baldan - Is MRI the gold standard to assess the response to neoadjuvant therapy? Ilaria Polico - Is MRI appropriate to plan the type of surgery? Alessandro Coran The audience will be asked to vote. After the vote, two senior speakers will debate items in favor or contra. The audience will be asked to vote again after the debate. 13.15 Lunch Pro: Pietro Panizza Contra: Petra Steyerova Conclusive remarks of the Chairmen 2 di 11
SESSION IV-STAGING AND ADJUVANT Chairmen: Cristina Ghiotto, Philip Poortmans 14.15 Appropriate staging work-up in early breast cancer Jassem Jacek 14.45 Is there a role for adjuvant bisphosphonates? Robert Coleman 15.15 Discussion SESSION V-GUIDELINES Chairmen: Cristina Ghiotto, Philip Poortmans 15.30 Role of guidelines in the era of personalized cancer medicine - do guidelines impact on patients outcome? Petra Boelens - genomics platforms as decision making tools - Miguel Martin 16.30 Adjourn 17.30 Ceremony for the presentation of the University of Padua Award for Advances Breast Cancer 2014 and the Monica Boscolo Research Grant 18.00 Lecture of the Awardee 18.30 Adjourn Friday, November 7 th SESSION VI-EARLY BREAST CANCER 9.00 Adjuvant Clinical Case Discussion I Chairmen: Pier Franco Conte, Miguel Martin Presenters of the cases: Zora Baretta, Cristina Falci The presenter will introduce a clinical case and will ask questions to the audience. The discussants will comment the vote and will review the state of art Discussants: - Fertility preservation - Lucia Del Mastro - Adjuvant therapy for low risk HER2+ patients - Valentina Guarneri - Endocrine adjuvant therapy in premenopause Stephen Johnston - Extended adjuvant endocrine therapy - Jonas Bergh 10.45 Discussion 11.00 Coffee break 3 di 11
11.30 Neoadjuvant Clinical Case Discussion II Chairmen: Fernando Bozza, Pier Franco Conte Presenters of the cases: Silvia Michieletto, Tania Saibene The presenter will introduce a clinical case and will ask questions to the audience. The discussants will comment the vote and will review the state of art. Discussants: - Locoregional management Philip Poortmans - HR+/HER2 negative Stephen Johnston - Triple negative breast cancer - Maria Vittoria Dieci - Adjuvant therapy in suboptimal responders after neoadjuvant therapy - Pier Franco Conte - 13.15 Discussion 13.30 Lunch SESSION VII -ADVANCED BREAST CANCER Chairmen: Valentina Guarneri, Sibylle Loibl 14.30 Clinical case discussion III The presenter will introduce a clinical case and will ask questions to the audience. The discussants will comment the vote and will review the state of art. 16.15 Discussion 16.30 Coffee break Sequence and duration of anti-her2 therapy Presenter: Cristina Falci Discussant: Pier Franco Conte Therapeutic options for HR+ disease Presenter: Carlo Alberto Giorgi Discussant: Gabriel N. Hortobagyi Triple negative advanced breast cancer. Presenter: Giovanni Faggioni Discussant: Sabine Linn Chairmen: Gabriel N. Hortobagyi, Donato Nitti 16.45 Clinical case discussion IV The presenter will introduce a clinical case and will ask questions to the audience. The discussants will comment the vote and will review the state of art. BRCA test as tool for therapy selection. Presenter: Zora Baretta Discussant: Miguel Martin Surgery of the primary in de novo stage IV disease. Presenter: Antonella Brunello Discussant: Miranda Ernst 4 di 11
18.00 Discussion 18.10 Adjourn Saturday, November 8 th SESSION VIII HIGHLIGHTS OF THE YEAR Chairmen: Jonas Bergh, Stefania Gori 9.00 Advances in biology Aleix Prat 9.30 HER2+ disease Fabio Puglisi 10.00 HR+/HER2- disease Stephen Johnston 10.30 Triple negative disease Cornelia Liedtke 11.00 Coffee break SESSION IX COMING SOON Chairmen: Gabriel N. Hortobagyi, Stephen Johnston 11.30 New promising drugs Jonas Bergh 12.00 Trials likely to impact on clinical practice in the near future: EBC Sibylle Loibl 12.30 Trials likely to impact on clinical practice in the near future: ABC Paolo Pronzato 13.00 Adjourn and final evaluation questionnaire [ Aims] Breast cancer mortality is declining in most countries; a detailed knowledge of the mechanisms of cancer progression, phenotypic and genotypic characterization of the disease, screening programs, advanced imaging, local therapies and molecularly targeted drugs have all been fundamental to achieve this success. Nowadays, breast cancer represents the front runner in the path to comparative effectiveness, where new therapeutic interventions are implemented on the basis of average benefit, to personalized cancer medicine, where the right treatment is provided to the right patient at the right moment. An updated, multifaceted approach to our patients is now becoming more and more demanding and with these goals in mind, the Programme of this international Conference includes lectures on molecular characterization, updated management of early and advanced disease, strategies to overcome resistance to available therapies, innovative therapies, and multimodal treatments for advanced disease. Clinical case discussions and debates are planned to allow a continuous and fruitful exchange of experiences and opinions between speakers and participants. 5 di 11
This 10 th Breast Cancer Conference includes a highly qualified international faculty, but will maintain its characteristics of a friendly forum where international opinion leaders and attendees will exchange experiences and share the most exiting advances. In order to reward scientific excellence and to foster international cooperation, the International Scientific Committee of the 10 th AIBCC will award the 4 th International Prize for Breast Cancer Research to a scientist who has published a breakthrough paper in the previous year and the Monica Boscolo Research Grant to an Italian scientist for a research project to be conducted in cooperation with a foreign institution. We welcome medical oncologists, pathologists, breast surgeons, radiation oncologists and basic scientists to listen to breast cancer leaders and to exchange experiences in a friendly atmosphere. [ Addressed to] Oncologists, pathologists, radiologists, radiation oncologists, surgeons, gynaecologists, biologists and nurses. [ Directors ] Pier Franco Conte Gabriel N. Hortobagyi Department of Breast Medical Oncology University of Texas - MD Anderson Cancer Center Houston (USA) [Scientific Committee] Jonas Bergh Department of Oncology-Pathology Karolinska Institute and University Hospital Stockholm (SW) Valentina Guarneri Jacek Jassem Department of Oncology and Radiotherapy Medical University of Gdansk (PL) Stephen Johnston NIHR Biomedical Research Centre for Cancer Royal Marsden NHS Foundation Trust & Institute of Cancer Research London (UK) 6 di 11
Sibylle Loibl German Breast Group Department of Medicine and Reasearch University of Frankfurt (D) Miguel Martin Medical Oncology Service Hospital Universitario Gregorio Maranon Madrid (S) Donato Nitti Philip Poortmans President-elect of ESTRO Department of Radiation Oncology Dr. Verbeeten Instituut Tilburg (NL) [Speakers] Alberto Amadori Division of Oncological Molecular Diagnostic and Immunology Enrica Baldan Breast Unit Nicola Balestrieri Breast Center AULSS 9 - Cà Foncello Hospital Treviso (I) Zora Baretta Jonas Bergh Department of Oncology-Pathology Karolinska Institute and University Hospital Stockholm (SW) 7 di 11
Giampaolo Bianchini Department of Medical Oncology IRCCS San Raffaele Hospital Milan (I) Petra Boelens Department of Surgery Leiden University Medical Center Leiden (NL) Fernando Bozza Division of Breast Surgery Antonella Brunello Division of Medical Oncology 1 Robert E. Coleman Academic Unit of Clinical Oncology Weston Park Hospital - University of Sheffield Sheffield (UK) Pier Franco Conte Alessandro Coran Breast Imaging Unit Alberto Costa European School of Oncology Milan (I) Lucia Del Mastro Medical Oncology A- Innovative therapies development National Institute for Cancer Research Genoa (I) Maria Vittoria Dieci Miranda Ernst Division of Oncology Surgery Alexander Monro Clinic Bilthoven (NL) 8 di 11
Giovanni Faggioni Cristina Falci Cristina Ghiotto Carlo Alberto Giorgi Stefania Gori Department of Medical Oncology Sacro Cuore - Don Calabria Hospital Negrar, VR (I) Valentina Guarneri Gabriel N. Hortobagyi Department of Breast Medical Oncology University of Texas - MD Anderson Cancer Center Houston (USA) Jacek Jassem Department of Oncology and Radiotherapy Medical University of Gdansk (PL) Stephen Johnston NIHR Biomedical Research Centre for Cancer Royal Marsden NHS Foundation Trust & Institute of Cancer Research London (UK) Cornelia Liedtke Campus Lübeck Department of Gynecology and Obstetrics University Hospital of Schleswig-Holstein Lubeck (D) Sabine Linn 9 di 11
Division of Molecular Pathology Netherlands Cancer Institute Amsterdam (NL) Sibylle Loibl German Breast Group Department of Medicine and Reasearch University of Frankfurt (D) Graziano Meneghini Breast Center ULSS 5 Ovest Vicentino Montecchio Maggiore (VI) Miguel Martin Medical Oncology Service Hospital Universitario Gregorio Maranon Madrid (S) Silvia Michieletto Division of Breast Surgery Donato Nitti Pietro Panizza Department of Diagnostic Radiology National Cancer Institute Milan (I) Luigi Pescarini Department of Radiology Diagnostic Breast Unit Ilaria Polico Breast Imaging Unit Philip Poortmans President of ESTRO Department of Radiation Oncology Dr. Verbeeten Instituut Tilburg (NL) 10 di 11
Aleix Prat Institute of Oncology (VHIO) Vall d Hebron Barcellona (E) Paolo Pronzato Department of Medical Oncology National Cancer Institute Genoa (I) Fabio Puglisi Department of Oncology University Hospital of Udine (I) Massimo Rugge General Pathology & Cytopathology Unit Department of Medicine-DIMED Tania Saibene Division of Breast Surgery Anna Sapino Department of Biomedical Science and Human Oncology University of Torino (I) Petra Steyerova Center for Breast Disease V. Polak Clinic of Radiology General University Hospital Prague (CS) [Meeting Venue] Centro Congressi Padova A. Luciani Via Forcellini, 170/A Padova tel. 049/8033711 11 di 11